Clinical trial
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in…
NCT00186940 · St. Jude Children's Research Hospital, Other · Completed
Key facts
| NCT number | NCT00186940 |
|---|---|
| Title | Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients |
| Official title | A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies |
| Lead sponsor | St. Jude Children's Research Hospital, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Leukemia, Lymphoma, Tumor Lysis Syndrome, Hyperuricemia |
| Intervention type | Drug |
| Interventions | Rasburicase |
| Enrollment | 16 |
| Start date | Mar 1, 2005 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Sep 16, 2005 |
| Last update posted | Apr 25, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: